Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer

Fig. 2

Construction of LM model and short-term oral absorption test in vivo. A Flow chart of LM model. H1975-luc cells were injected through the right ventricle. Representative images of B IVIS imaging, C MRI at week 2 after injection tumor cells, and E the leptomeningeal tissue of normal group and LM group was compared by H&E staining. D Concentration of osimertinib in the mouse brain tissue in 1,6,12,24 h after single dose of osimertinib with or without bevacizumab (n = 3, * means p < 0.05, *** means p < 0.001)

Back to article page